Skip to content

effect and safety of turmeric on vascular function in diabetics

Efficacy and safety of Curcuma longa on cardiac endothelial function in native Tamilians with type 2 diabetes mellitus: A randomized, double blind, parallel arm, placebo controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/10/007401
Enrollment
154
Registered
2016-10-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 diabetes mellitus patients Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Curcuma longa capsules: Curcuma longa capsules 400mg tds for 3 months in addition to standard background therapy(metformin with or without sulfonylureas) Control Intervention1: Placebo

Sponsors

JIPMER Intramural fund
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Native Tamilian patients with type 2 diabetes mellitus diagnosed within the past 3 months to 10 years, on stable dose of metformin with or without sulfonylureas, for at least past 3 months

Exclusion criteria

Exclusion criteria: 1) Liver dysfunction (AST,ALT > 2 times the upper limit of normal) 2) Renal dysfunction (GFR 3) Patient with concurrent illnesses like CAD(Coronary Artery Disease), CVA( cerebrovascular accidents), PVD(Peripheral Vascular Disease), CKD( Chronic Kidney Disease)other than hypertension 4) Patients taking anti diabetic drugs other than metformin and sulfonylureas 5) Pregnant women or lactating mothers; women in reproductive age group not practicing contraceptive measures. 6) Patients who had participated in other trials in the past three months. 7) Those on other herbal medications. 8) Current smokers 9) alcoholics 10) Patients with active infections such as diabetic foot infection etc

Design outcomes

Primary

MeasureTime frame
carotid femoral pulse wave velocityTimepoint: baseline,1st,2nd,3rd month

Secondary

MeasureTime frame
1.arterial stiffness index, ankle brachial index, aortic systolic/diastolic pressures, augmentation pressure, augmentation index 2. ICAM and VCAM 3. adiponectin and leptin 4. the adverse drug reactions(ADR)to Curcuma longaTimepoint: 1.At baseline, At the end of 1st month, 2nd month and 3rd month 2.baseline and 3 months 3.baseline and 3 months 4.1st,2nd and 3rd month

Countries

India

Contacts

Public ContactDr Sandhiya S

JIPMER

steven_d44@rediffmail.com9894322448

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026